← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2000First marketed drug
Jun 1, 1962First NDA
Jun 1, 1962Last known activity
Sep 1, 2025
Acquired by Abbott on Jan 1, 2009
Timeline
1860s
- Jul 1, 1863
Solvay— Founded
1960s
- Jun 1, 1962
dydrogesterone— NDA Organization
- Jan 27, 1967
meprobamate— NDA Secondary Org
1970s
- Apr 28, 1978
medroxyprogesterone— Marketing Organization
1980s
- Jan 1, 1986
Reid-Rowell, Inc— Acquired
1990s
- Jan 1, 1990
Philips— Acquired
- Jan 1, 1999
Unimed Pharmaceuticals— Acquired
2000s
- Jan 1, 2005
Fournier Labs— Acquired - Jan 1, 2009
Abbott— Acquired By
2010s
- Oct 7, 2013
Chemlogics— Acquired
- Mar 26, 2014
Plextronics— Acquired
Drugs by trial phase (94 distinct, 162 trials)
Phase 4 (15 own, 6 via acquisition)
Phase 3 (22 own, 5 via acquisition)
Phase 2 (8 own, 5 via acquisition)
Phase 1 (7 own, 7 via acquisition)
Other trials (14 own, 5 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Amenorrhea
- Apnea
- Atherosclerosis
- Atrial Fibrillation
- Atrial Flutter
- Atrophy
- Bipolar Disorder
- Body Weight Changes
- Bone Diseases, Metabolic
- Brain Neoplasms
- Cardiovascular Diseases
- Chronic Pain
- Cognitive Dysfunction
- Compulsive Personality Disorder
- Coronary Artery Disease
- Coronary Disease
- Cystic Fibrosis
- Dementia
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Dyslipidemias
- Endometriosis
- Eructation
- Exocrine Pancreatic Insufficiency
- Fibrosis
- Fissure in Ano
- Frailty
- Glioma
- Glucose Metabolism Disorders
- Headache
- Heart Failure
- Hemorrhoids
- Hip Fractures
- HIV Infections
- Hot Flashes
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperplasia
- Hypertension
- Hypertriglyceridemia
- Hypogonadism
- Influenza, Human
- Insulin Resistance
- Kidney Diseases
- Major Depressive Disorder
- Meniere Disease
- Mental Disorders
- Metabolic Diseases
- Metabolic Syndrome
- Migraine Disorders
- Migraine with Aura
- Migraine without Aura
- Myocardial Ischemia
- Nausea
- Neoplasm Metastasis
- Neuralgia
- Neuralgia, Postherpetic
- Obesity
- Obsessive-Compulsive Disorder
- Osteoarthritis
- Osteoarthritis, Knee
- Overweight
- Pancreatitis
- Pancreatitis, Chronic
- Parkinson Disease
- Problem Behavior
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Psychotic Disorders
- Renal Insufficiency
- Schizophrenia
- Sleep Apnea Syndromes
- Syndrome
- Vomiting
- Weight Loss
Marketed drugs (35)
Subsidiaries (6 direct, 12 total across the full acquisition tree)
Recent trials (50)
- NCT06877364Lead sponsorPhase 1/Phase 2Sep 1, 2025
- NCT06911983Lead sponsorN/AJul 1, 2025
- NCT06863935Lead sponsorN/AMay 10, 2024
- NCT06867939Lead sponsorN/AMay 5, 2024
- NCT06863922Lead sponsorN/AMay 3, 2024
- NCT06269406Lead sponsorN/AMar 10, 2024
- NCT06914921Lead sponsorN/AFeb 4, 2024
- NCT06470425Lead sponsorN/AFeb 2, 2024
- NCT06914934Lead sponsorN/AFeb 1, 2024
- NCT06215196Lead sponsorN/AApr 14, 2023
- NCT06470399Lead sponsorN/AFeb 2, 2023
- NCT06163443Lead sponsorN/AMar 2, 2022
- NCT06154408Lead sponsorN/AFeb 10, 2022
- NCT01088594Lead sponsorPhase 1Feb 1, 2010
- NCT01088594Study directorPhase 1Feb 1, 2010
Details
- Founded
- Brussels, BE Jul 1, 1863
- First NDA
- Jun 1, 1962
- Last known activity
- Sep 1, 2025